Adult AML patient characteristics
| Characteristics . | All patients . | Low VEGFC . | High VEGFC . |
|---|---|---|---|
| No. of patients | 525 | 262 | 262 |
| Median age, y (range) | 46.6 (15.2-77.2) | 43.7 (15.2-75.5) | 49.7 (15.8-77.2) |
| Median WBC, ×109/L (range) | 26 (0.3-510) | 34 (0.6-510) | 20 (0.3-349) |
| Median blasts, % (range) | 65 (1-99) | 70 (2-99) | 62 (1-99) |
| Median platelets, ×109/L (range) | 56 (3-998) | 53 (6-494) | 59 (3-998) |
| Cytogenetic risk | |||
| Favorable | 89 (17%) | 57 (22%) | 32 (12%) |
| t(8;21) | 34 | 23 | 11 |
| t(15;17) | 20 | 12 | 8 |
| inv16 | 35 | 22 | 13 |
| Intermediate | 331 (63%) | 164 (63%) | 166 (63%) |
| Normal karyotype | 218 | 111 | 107 |
| + 8 | 25 | 8 | 16 |
| −9q | 7 | 4 | 3 |
| Other | 81 | 41 | 40 |
| Unfavorable | 85 (16%) | 34 (13%) | 51 (19%) |
| 11q23 | 11 | 6 | 5 |
| Complex | 20 | 7 | 13 |
| −5(q)/−7(q) | 42 | 16 | 26 |
| abn(3q) | 2 | 1 | 1 |
| t(6;9) | 6 | 3 | 3 |
| t(9;22) | 2 | 1 | 1 |
| Other | 2 | 0 | 2 |
| Not available | 20 (4%) | 7 (3%) | 13 (5%) |
| FLT3-ITD vs no FLT3-ITD | 143/382 | 68/194 | 74/188 |
| NPM1 wild type vs mutant | 366/159 | 184/78 | 181/81 |
| CEBPA wild type vs mutant* | 486/38 | 240/22 | 245/16 |
| Allogeneic SCT | 140† | 66‡ | 74§ |
| Autologous SCT | 68 | 40 | 28 |
| Cycles to CR | |||
| 1 | 297 (57%) | 149 (57%) | 147 (56%) |
| 2 | 111 (21%) | 67 (25%) | 44 (17%) |
| 3 | 8 (2%) | 6 (2%) | 2 (1%) |
| More than 3 | 5 (1%) | 2 (1%) | 3 (1%) |
| No CR | 104 (20%) | 38‖ (15%) | 66‖ (25%) |
| Relapse | 202 (39%) | 97 (37%) | 105 (40%) |
| Dead vs alive | 316/209 | 141/121‖ | 174/88‖ |
| Characteristics . | All patients . | Low VEGFC . | High VEGFC . |
|---|---|---|---|
| No. of patients | 525 | 262 | 262 |
| Median age, y (range) | 46.6 (15.2-77.2) | 43.7 (15.2-75.5) | 49.7 (15.8-77.2) |
| Median WBC, ×109/L (range) | 26 (0.3-510) | 34 (0.6-510) | 20 (0.3-349) |
| Median blasts, % (range) | 65 (1-99) | 70 (2-99) | 62 (1-99) |
| Median platelets, ×109/L (range) | 56 (3-998) | 53 (6-494) | 59 (3-998) |
| Cytogenetic risk | |||
| Favorable | 89 (17%) | 57 (22%) | 32 (12%) |
| t(8;21) | 34 | 23 | 11 |
| t(15;17) | 20 | 12 | 8 |
| inv16 | 35 | 22 | 13 |
| Intermediate | 331 (63%) | 164 (63%) | 166 (63%) |
| Normal karyotype | 218 | 111 | 107 |
| + 8 | 25 | 8 | 16 |
| −9q | 7 | 4 | 3 |
| Other | 81 | 41 | 40 |
| Unfavorable | 85 (16%) | 34 (13%) | 51 (19%) |
| 11q23 | 11 | 6 | 5 |
| Complex | 20 | 7 | 13 |
| −5(q)/−7(q) | 42 | 16 | 26 |
| abn(3q) | 2 | 1 | 1 |
| t(6;9) | 6 | 3 | 3 |
| t(9;22) | 2 | 1 | 1 |
| Other | 2 | 0 | 2 |
| Not available | 20 (4%) | 7 (3%) | 13 (5%) |
| FLT3-ITD vs no FLT3-ITD | 143/382 | 68/194 | 74/188 |
| NPM1 wild type vs mutant | 366/159 | 184/78 | 181/81 |
| CEBPA wild type vs mutant* | 486/38 | 240/22 | 245/16 |
| Allogeneic SCT | 140† | 66‡ | 74§ |
| Autologous SCT | 68 | 40 | 28 |
| Cycles to CR | |||
| 1 | 297 (57%) | 149 (57%) | 147 (56%) |
| 2 | 111 (21%) | 67 (25%) | 44 (17%) |
| 3 | 8 (2%) | 6 (2%) | 2 (1%) |
| More than 3 | 5 (1%) | 2 (1%) | 3 (1%) |
| No CR | 104 (20%) | 38‖ (15%) | 66‖ (25%) |
| Relapse | 202 (39%) | 97 (37%) | 105 (40%) |
| Dead vs alive | 316/209 | 141/121‖ | 174/88‖ |
Cytogenetic risk group distinction (favorable, intermediate, and unfavorable) is described in “Patients.”
Low VEGFC indicates a VEGFC mRNA expression level below the median VEGFC level; high VEGFC, a VEGFC mRNA expression level above the median VEGFC level; WBC, white blood cell count; NPM1, nucleophosmin 1; FLT3, fms-related tyrosine kinase 3; ITD, internal tandem duplication; CEBPA, CCAAT/enhancer binding protein α; SCT, stem cell transplantation; and CR, complete remission.
For 1 patient, the CEBPA status is unknown.
Twelve of 140 patients with an allogeneic SCT after nonmyeloablative conditioning.
Four of 66 patients with an allogeneic SCT after nonmyeloablative conditioning.
Eight of 74 patients with an allogeneic SCT after nonmyeloablative conditioning.
A significant difference when AML patients with a low versus high VEGFC expression level were compared (P < .01).